ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Blocking Complement Component C3 in a Sensitized Nonhuman Primate Model of Kidney Allotransplantation

R. Schmitz1, P. M. Schroder1, Z. W. Fitch1, A. Y. Choi1, M. Manook1, J. Yoon1, A. Farris2, E. S. Reis3, J. D. Lambris3, J. Kwun1, S. J. Knechtle1

1Department of Surgery, Duke University Medical Center, Durham, NC, 2Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Meeting: 2020 American Transplant Congress

Abstract number: C-368

Keywords: Alloantibodies, Graft survival, Highly-sensitized, Rejection

Session Information

Session Name: Poster Session C: Immunosuppression Preclinical Studies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Sensitized transplant recipients represent a challenge due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection. Complement inhibition has been shown to protect the graft against DSA; however, strategies target classical pathway activation, or terminal effectors such as C5b-9. We hypothesized that targeting C3 at the time of transplant can prevent both direct antibody mediated damage, and abrogate immune responses.

*Methods: Eleven (11) rhesus macaques were sensitized to maximally MHC mismatched donors by two sequential skin transplants. Primates subsequently received kidney allografts from their skin donors without prior desensitization therapy. All primates received induction therapy with rhesus specific anti-thymocyte globulin (rhATG) and maintenance immunosuppression with tacrolimus, mycophenolate mofetil and prednisone. A subset of 6 primates was additionally treated with the C3 complement inhibitor Compstatin for 14 days after kidney transplantation.

*Results: No difference in preformed DSA levels was observed prior to kidney transplantation between groups (mean MFI 909 vs. 1019, p=0.64). The addition of Compstatin significantly prolonged the median graft survival from 4 days in the control group to 15.5 days (p=0.028, Figure 1a), with reduced antibody-mediated injury on protocol kidney biopsies. The longest graft survival was 48 days. While all primates showed a significant increase in DSA after transplant, Compstatin enabled primates to maintain kidney function for up to 1 month beyond the last day of administration (POD14) in the presence of high serum DSA level (Figure 1b). Compstatin did not significantly alter T cell depletion by rhATG. However, we observed a significantly lower frequency of Ki67+ proliferating T cells (34.2% vs. 14.9%, p=0.004) and CD69+ activated T cells (25.7% vs. 16.4%, p=0.01) in the Compstatin group immediately post-transplant.

*Conclusions: Compstatin treatment significantly prolonged graft survival in a sensitized NHP kidney allotransplantation model, and protected the graft against acute antibody mediated injury in spite of high serum DSA levels. Under Compstatin, T cell activation and proliferation were decreased, suggesting an immunomodulatory effect of this therapy.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Schmitz R, Schroder PM, Fitch ZW, Choi AY, Manook M, Yoon J, Farris A, Reis ES, Lambris JD, Kwun J, Knechtle SJ. Blocking Complement Component C3 in a Sensitized Nonhuman Primate Model of Kidney Allotransplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/blocking-complement-component-c3-in-a-sensitized-nonhuman-primate-model-of-kidney-allotransplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences